|
|
|
European Biopharmaceutical Review
|
| Proteomics activity in the biotech and pharmaceutical
industries has shifted in recent years from technology-focused
and centralised discovery programmes, to enabling facilities
integrated into discovery and production departments, using
highly specialised state-of-the-art proteomics techniques.
These are utilised for biomarker and target discovery and
the development of protein therapeutics. Applications for
proteomics techniques include antigen discovery, proteinprotein
interaction studies, differential protein display between
treated and non treated proteomes from preclinical studies
(for example cell culture model), but also in upstream and
downstream process optimisation.
Also, state-of-the-art
protein analytics developed for proteomics applications are
applied for full characterisation of protein therapeutics in its
structural characterisation, physiochemical properties and
its process- and product-related impurities analysis following
ICH Q6B.
State-of-the-art techniques for the analysis of complex proteomes
and protein mixtures use multidimensional approaches: separation
at a protein level (1D/2D PAGE); different separation principles
at a peptide level (IEF, 1D LC and 2D LC workflows); and a
combination of different mass spectrometry-based techniques
(electrospray ionisation and MALDI-laser based ionisation, iontrap
or time-of-flight analysers to generate MS and MS-MS data). |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Dr Herbert Thiele was educated at the
Institute of Organic Chemistry, TH Aachen,
where he gained his diploma and wrote his
doctoral thesis. He started out in 1977 as
a teacher of Chemistry and Mathematics
at the Fachschule des Heeres für Technik/
Aachen. He joined Bruker in 1978 and has held various
management positions, as well as being made an Honorary
Professor in Analytical Chemistry at the University of Bremen.
In 2002 he was appointed Director of Bioinformatics.
Martin Blüggel earned a diploma in
Chemistry at the University of Konstanz,
specialising in proteins. After working as a
researcher, he founded, along with Prof H E
Meyer, Protagen GbR, a company devoted
to peptide and protein analysis. In 1999,
this venture became Protagen AG, and Martin was appointed
Chief Operating Officer in 2002. He is responsible for
management of customer projects, and coordinating
Protagen´s resources across the various operating entities. |
|
|
|
|
|
 |
Industry Events |
 |
3rd African Regulatory Conference (ARC)
3-4 May 2012, Accra, Ghana
The African Regulatory Conference offers the opportunity for key stakeholders active on the continent, including representatives from Ministry of Health, local and multinational pharmaceutical companies, to meet to exchange views, discuss topics of interest and identify focus areas for ongoing efforts to increase patient access to new and improved medicines.
More info >> |
|
 |
News and Press Releases |
 |
The Marketing Machine Helps International Pharma Client with Ambitious Literacy Drug Packaging Rebrand
Full-service advertising and branding firm The Marketing Machine recently finished an ambitious, innovative rebranding project for Danadams Pharmaceuticals Industry Limited to help overcome literacy and distribution challenges with patients in Ghana, South Africa. The firm utilized its award-winning design services team to redesign all of Danadams branding and packaging using intuitive visual icons and color elements to indicate the type of drugs and dosages and better display information more clearly and legibly. Danadams Pharmaceuticals is currently the only manufacturer of anti-retroviral drugs in West Africa. It also manufactures and sells anti-malarials, antibiotics, analgesics and other opportunistic infection drugs for the West African market.
More info >> |
|
|
